Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ArdelyxFRA:41X -1.62%69 Days Payable is 526.88 as of Jun. 2026, which is 21% below its 10-year median of 670.95. GuruFocus rates FRA:41X with a GF Score™ of 69/100 and a GF Value™ of €7.79 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 703 Biotechnology companies, Ardelyx ranks better than 74.4% on this metric.
Ardelyx's average Accounts Payable for the
three
months ended in Jun. 2026 was €28.9 Mil. Ardelyx's Cost of Goods Sold for the
three
months ended in Jun. 2026 was €5.0 Mil.
Hence, Ardelyx's Days Payable for the
three
months ended in Jun. 2026 was 526.88.
The historical rank and industry rank for Ardelyx's Days Payable or its related term are showing as below:
FRA:41X'
s Days Payable Range Over the Past 10 Years
Min: 97.96 Med: 670.95 Max: 9833.6
Current: 361.87
During the past 13 years, Ardelyx's highest Days Payable was 9833.60. The lowest was 97.96. And the median was 670.95.
FRA:41X's Days Payable is ranked better than 74.4% of 703
companies
in the Biotechnology industry
Industry Median: 112.39
vs FRA:41X: 361.87
Ardelyx's Days Payable
increased
from Jun. 2025 (133.63) to Jun. 2026 (526.88).
It may suggest that Ardelyxdelayed paying its suppliers.
The historical data trend for Ardelyx's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:41X vs IMTX, TRAX, AVLN: Days Payable Comparison
For the Biotechnology subindustry, Ardelyx's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ardelyx Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ardelyx's Days Payable distribution charts can be found below:
* The bar in red indicates where Ardelyx's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Ardelyx's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ardelyx (FRA:41X) has a Days Payable of 526.88 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Ardelyx and its competitors. This is 21% below median its historical median of 670.95. Over the past decade, Ardelyx's Days Payable has ranged from 97.96 to 9,833.60. According to the industry distribution chart, Ardelyx ranks #180 out of 703 companies in the Biotechnology industry, placing it in the top 25.6%.
Is Ardelyx's Days Payable too high?
Ardelyx's current Days Payable of 526.88 is 21% below median its 10-year median of 670.95. Over the past 10 years, this metric has ranged from a low of 97.96 to a high of 9,833.60. The Biotechnology industry median Days Payable is 112.39. Ardelyx's value of 526.88 is 368.8% above this industry median. Based on the distribution chart, Ardelyx ranks #180 out of 703 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ardelyx has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ardelyx's Days Payable compare to IMTX and TRAX?
According to the Biotechnology industry distribution chart, Ardelyx ranks #180 out of 703 companies for Days Payable. This puts Ardelyx in the upper half of its industry. The industry median Days Payable is 112.39. Ardelyx's value of 526.88 is 368.8% above this benchmark. Historically, Ardelyx's own Days Payable has ranged from 97.96 to 9,833.60 over the past decade. While the company's 10-year median is 670.95 vs. the industry median of 112.39, Ardelyx has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.39, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ardelyx's current Days Payable of 526.88 is 368.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Ardelyx and its competitors. For the Biotechnology industry, the median Days Payable is 112.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ardelyx's current Days Payable is 526.88, which is 21% below median its own 10-year median of 670.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ardelyx stock overvalued right now?
Based on GuruFocus' analysis, Ardelyx (FRA:41X) is currently considered Possible Value Trap. The stock's GF Value™ is €7.79, compared to a current price of €3.34 — trading 57.1% below its estimated fair value. The current Days Payable is 526.88, which is 21% below median its 10-year median of 670.95 and 368.8% above the Biotechnology industry median of 112.39. Ardelyx's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Ardelyx (FRA:41X), the current Days Payable is 526.88 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ardelyx (FRA:41X) Overvalued in 2026?
Based on GuruFocus' analysis, Ardelyx stock appears to be undervalued.
The current stock price of €3.34 is trading 57.1% below its estimated GF Value™ of €7.79.
GuruFocus considers Ardelyx to be Possible Value Trap.
Key valuation signals for FRA:41X:
Days Payable: 526.88 (21% below median its 10-year median of 670.95)
GF Value™: €7.79 vs. price of €3.34 (57.1% below fair value)
Industry Position: 368.8% above the Biotechnology median (#180 of 703)
No single metric tells the full story. See the FRA:41X stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
69GF Score
Get the complete analysis for FRA:41X
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:41X has been successfully added to your 
